Biogen Turns In Robust Quarter, Fueled By Avonex; Late-Stage Commercial Catalysts Abound

In the second quarter, Biogen demonstrated a continuing ability to milk revenue from established MS products while it prepares to launch a wave of potentially market-shifting NMEs.